Dishman Carbogen Amcis Ltd. (DCAL) AI Stock Analysis

• Market Cap: ₹45.74B
• Dividend Yield: N/A
• Average Volume (3M): 21.78K
• Price to Earnings (P/E): 43.9
• Beta (1Y): 1.33
• Revenue Growth: 19.85%
• EPS Growth: N/A
• Country: IN
• Employees: 1,132
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.49
• Shares Outstanding: 156,783,100
• 10 Day Avg. Volume: 7,151
• 30 Day Avg. Volume: 21,777
• PEG Ratio: -10.28
• Price to Book (P/B): 0.58
• Price to Sales (P/S): 1.25
• P/FCF Ratio: 21.46
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 69 Neutral
• Price Target: ₹323.00 ▲(14.72% Upside)

The overall stock score reflects strong technical indicators and solid financial performance, albeit with low net profitability. The high P/E ratio suggests overvaluation, which could limit future gains unless earnings growth improves. The absence of earnings call data and corporate events means these factors did not influence the score.

Dishman Carbogen Amcis Ltd. Business Overview & Revenue Model

Company Description

Dishman Carbogen Amcis Ltd. (DCAL) is a global contract development and manufacturing organization (CDMO) specializing in the pharmaceutical and biotechnology sectors. The company provides a comprehensive range of services including active pharmaceutical ingredient (API) development, manufacturing, and custom synthesis. DCAL focuses on delivering high-quality, cost-effective solutions across various therapeutic areas, catering to both large pharmaceutical companies and emerging biotech firms.

How the Company Makes Money

DCAL generates revenue primarily through its contract manufacturing and development services. The company earns money by engaging in contracts with pharmaceutical and biotech clients for the production of APIs and intermediates, as well as offering research and development support. Key revenue streams include fees for manufacturing services, project management, and consultancy related to drug development. DCAL also benefits from partnerships with major pharmaceutical firms, enhancing its market reach and credibility. Additionally, its ability to innovate and adapt to client needs contributes to client retention and repeat business, further solidifying its financial performance.

Dishman Carbogen Amcis Ltd. Financial Statement Overview

Summary

Dishman Carbogen Amcis Ltd. demonstrates strong revenue growth and efficient operational performance with a healthy gross profit margin. However, the net profit margin is low, indicating challenges in converting revenue into net income. The balance sheet is stable with moderate leverage, and cash flow generation is solid, though there is room for improvement in translating profits into free cash flow.

Income Statement

Dishman Carbogen Amcis Ltd. has shown strong revenue growth over the years, with the latest year reporting a 6.61% increase in revenue. Gross profit margin is healthy at 81.49%, indicating efficient cost management. However, the net profit margin remains low at 0.12%, reflecting challenges in converting revenue into net income despite improvements from negative margins in prior years. The EBIT and EBITDA margins demonstrate recovery from previous losses, signaling enhanced operational efficiency.

Balance Sheet

The balance sheet shows a solid equity base with an equity ratio of 58.31%, indicating a stable financial position. The debt-to-equity ratio stands at 0.41, reflecting manageable leverage levels. Return on equity is modest at 0.06%, suggesting limited profitability on shareholders' investment. Overall, the company maintains a sound financial structure with moderate leverage.

Cash Flow

The company reported positive free cash flow growth of 96.36%, indicating effective cash management. The operating cash flow to net income ratio of 115.79 suggests robust cash generation relative to net income. However, the free cash flow to net income ratio is lower at 49.05%, pointing to room for improvement in translating profits into free cash flow.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	28.96B	27.11B	26.16B	23.15B	21.41B	19.12B
Gross Profit	23.62B	22.10B	18.45B	17.81B	16.82B	14.28B
EBITDA	6.10B	4.73B	3.07B	3.08B	3.43B	2.86B
Net Income	1.04B	32.40M	-1.53B	-298.00M	180.10M	-1.65B
Balance Sheet
Total Assets	0.00	99.99B	95.81B	94.53B	86.37B	83.66B
Cash, Cash Equivalents and Short-Term Investments	5.32B	5.32B	4.31B	3.09B	4.67B	4.31B
Total Debt	0.00	23.89B	23.13B	22.09B	18.30B	15.89B
Total Liabilities	-58.32B	41.68B	39.54B	36.44B	30.89B	26.67B
Stockholders Equity	58.32B	58.32B	56.27B	58.10B	55.49B	56.99B
Cash Flow
Free Cash Flow	0.00	1.58B	807.20M	-3.54B	-1.09B	1.47B
Operating Cash Flow	0.00	3.75B	3.84B	2.66B	3.55B	5.13B
Investing Cash Flow	0.00	-1.92B	-2.30B	-4.94B	-6.19B	-3.81B
Financing Cash Flow	0.00	-1.02B	-221.50M	2.50B	1.30B	-110.40M

Dishman Carbogen Amcis Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 281.55
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:DCAL, the sentiment is Positive. The current price of 281.55 is below the 20-day moving average (MA) of 287.99, above the 50-day MA of 281.41, and above the 200-day MA of 246.49, indicating a bullish trend. The MACD of 3.09 indicates Negative momentum. The RSI at 53.93 is Neutral, neither overbought nor oversold. The STOCH value of 69.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:DCAL.

Dishman Carbogen Amcis Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SYNGENE	―	₹257.22B	50.51	―	0.19%	7.41%	2.88%
DCAL	―	₹45.74B	43.89	―	―	19.85%	―
JUBLINGREA	―	₹109.79B	37.75	―	0.73%	3.80%	64.94%
CONCORDBIO	―	₹160.40B	45.04	―	0.73%	14.49%	13.70%
BIOCON	―	₹496.41B	116.06	―	0.13%	6.80%	-75.66%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PANACEABIO	―	₹26.56B	231.39	―	―	11.80%	―

Dishman Carbogen Amcis Ltd. Corporate Events

Dishman Carbogen Amcis Limited Announces Postal Ballot Results

Dishman Carbogen Amcis Limited, a company listed on BSE and NSE, has announced the results of its postal ballot where shareholders approved five resolutions. These include increasing the authorized share capital, altering the capital clause of the Memorandum of Association, raising funds through various methods, re-appointing Mrs. Deohooti J. Vyas as a Whole-time Director, and confirming the appointment of Mr. Dhaval Rameshchandra Shah as a Non-Executive and Non-Independent Director. The resolutions were approved with the requisite majority, and the e-voting was facilitated by Central Depository Services (India) Limited.

Dishman Carbogen Amcis Ltd. Releases Investor Presentation

Dishman Carbogen Amcis Ltd. has released an investor presentation in compliance with SEBI regulations, which is now available on their website. This move is part of the company’s commitment to transparency and regular communication with stakeholders, potentially impacting investor relations positively.

Dishman Carbogen Amcis Ltd. Announces Virtual AGM for 2025

Dishman Carbogen Amcis Ltd. has announced that its 18th Annual General Meeting will be held on September 29, 2025, via video conferencing. This move aligns with regulatory guidelines and ensures shareholder participation in company decisions, reflecting the company’s commitment to transparency and stakeholder engagement.